---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116598"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:48:32.359842+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Milestone's etripamil Phase 2 meets primary endpoint; 30 bpm ventricular rate reduction vs placebo

## Summary
- Mean ventricular rate reduction of 29.91 bpm vs placebo (p<0.0001); absolute max reduction 35 bpm etripamil vs 5 bpm placebo.
- 58.3% of etripamil patients achieved <100 bpm vs 4% placebo; median time to max reduction 13 min, effect ~150 min.
- TSQM-9 patient-reported symptom relief significantly improved: effectiveness (p<0.0001) and relief of symptoms (p=0.0002).
- Safety consistent with PSVT program; SAEs rare: one patient with transient severe bradycardia/syncope resolved.
- Company plans Phase 3 trial; NDA for etripamil in PSVT already submitted with FDA.

## SEC filing metadata
- accession: 0001104659-23-116598
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465923116598/0001104659-23-116598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465923116598/tm2330492d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116598
- JSON: https://secwatch.observer/filing/0001104659-23-116598.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.